As anticipated, Pfizer (NYSE: PFE) has secured US Food and Drug Administration approval for its bivalent RSV vaccine, targeting disease caused by RSV in people over the age of 60.
The historic milestone - bringing to market new protection against a virus that has previously had no vaccine - comes just a couple of months after GSK’s (LSE: GSK) Arexvy also won approval from the agency in this indication.
Pfizer is also expected to win approval to treat babies, after a positive recommendation from the US FDA’s scientific advisory panel.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze